** Shares of drugmaker SpringWorks Therapeutics SWTX.O rise 10.12% to $61.37 premarket
** Co says it will not host a conference call to discuss its quarterly earnings, which Evercore ISI analysts say confirms that its negotiations with Germany's Merck KGaA MRCG.DE for a potential buyout "are still very much alive"
** Reuters reported on February 10 that Germany's Merck KGaA MRCG.DE was in advanced talks to acquire the company; Merck subsequently confirmed the talks
** Separately, SpringWorks posts Q4 revenue of $61.5 mln, versus analysts' est of $59.1 mln, as per data compiled by LSEG
** "This morning's 4Q print is in-line (recall January pre-announcement) and irrelevant," says Evercore ISI
** Stock has risen 3.2% since the Reuters report and 13.5% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.